Goldman Sachs is shifting its investment focus beyond crowded AI stocks, identifying China’s healthcare sector as a key growth area. Robust corporate earnings in China, particularly in pharmaceuticals, are signaling untapped potential for investors. The firm’s analysis highlights companies with strong earnings growth projections, suggesting a strategic move towards sectors poised for significant expansion.
Goldman Sachs Bets on China's Healthcare Sector for Post-AI Investment Growth
Original Title: Goldman picks China healthcare stocks for a post-AI trade
As the global investment landscape shifts from the fervor of artificial intelligence, Goldman Sachs is identifying new frontiers for growth. The investment bank's latest analysis suggests that China's healthcare sector, particularly pharmaceuticals, presents a compelling opportunity for investors seeking returns beyond the increasingly concentrated AI market. This strategic pivot comes as Chinese corporate earnings demonstrate robust growth, with nearly half of the MSCI China index constituents exceeding expectations in the second quarter.
Earnings Surge and the AI Exodus
Chinese stocks tracked by Goldman Sachs experienced their highest quarterly earnings growth in five years, surging by 24% in the second quarter compared to the previous year. This acceleration from a modest 6% in the first quarter was largely fueled by artificial intelligence-related companies. However, Goldman Sachs analysts note that as AI stocks become more crowded, investors are actively seeking diversified growth avenues. Their research indicates that discussions in earnings calls are expanding from AI hardware and semiconductors into downstream sectors like data centers, AI models, automotive, and critically, healthcare.
Goldman's Screening Methodology
To pinpoint potential investment winners, Goldman Sachs employed a stringent screening process. They focused on Chinese companies within their buy-rated coverage that are projected to achieve over 15% annual earnings growth through 2027. Additionally, they looked for companies that have seen a median increase of 7% in their earnings per share estimates over the past month. The methodology favored stocks where Goldman's own earnings estimates surpassed market consensus, signaling potential for upward revisions.
Healthcare: The Promising Frontier
The screening process highlighted healthcare, especially pharmaceutical stocks, as a significant area of opportunity. These companies accounted for one-third of the twelve stocks that made Goldman's final selection list. Notable mentions include:
- Innovent Biologics (Suzhou): Expected to more than double its earnings in the coming year, with Goldman's estimates significantly exceeding consensus. The company boasts a pipeline of treatments for cancer and metabolic diseases.
- BeOne Medicines (Shanghai): Also projected to more than double its earnings within the next year. This cancer treatment developer is listed on Nasdaq and Hong Kong.
- CSPC (Hong Kong): Forecasted to achieve 26% earnings growth. Its core businesses encompass nervous system and cardiovascular drugs.
- Hansoh Pharma (Hong Kong): Anticipated to grow earnings by 15%. The company's product portfolio includes treatments for metabolic disorders and cancer.
If these four companies meet their forecasts, their growth rates would surpass Goldman's conservative expectation of 8% earnings growth for the broader MSCI China index this year, which contrasts with the consensus forecast of 17%.
This report was contributed to by CNBC's Michael Bloom.
